Skip to main
LPCN

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine Inc. is advancing its clinical-stage pipeline with LPCN 1154, an oral formulation of brexanolone that demonstrates a significant improvement in efficacy and safety compared to existing treatments, supported by a favorable safety profile with no reports of severe adverse events. The company’s strategic focus on drug delivery solutions, including its flagship product TLANDO and other promising candidates, positions it well within the biopharmaceutical sector. Despite a net loss of $3.2 million reported, there is optimism surrounding its potential for a 505(b)(2) new drug application submission, which could catalyze future financial growth and investment interest.

Bears say

Lipocine Inc. reported a net loss of $3.2 million in the third quarter of 2025, indicating ongoing financial challenges as the company navigates its clinical development stage. The company's prospects are overshadowed by significant risks associated with its lead product candidate, LPCN 1154, including potential failure in clinical trials, regulatory approval hurdles, and commercial viability issues such as reimbursement and competition. Additionally, concerns about dilution risk further exacerbate the negative outlook for Lipocine's stock, as these factors contribute to uncertainty and instability in the company's financial future.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.